This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.

Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.

Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: ##STR00001## wherein J.sup.1 and J.sup.2 each represent CH or N, with the proviso that J.sup.1 and J.sup.2 are not simultaneously CH; r represents 0 to 4; each R.sup.101 is the same or different when r is 2 or more, and R.sup.101 represents a C.sub.1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R.sup.102 is the same or different when s is 2 or more, and R.sup.102 represents a halogen atom or the like; R.sup.103 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-6 cycloalkyl group, or a C.sub.3-6 cycloalkyl C.sub.1-6 alkyl group; and R.sup.101 and R.sup.103 are optionally linked together to form a five- to seven-membered ring hetero ring when R.sup.101 is present at the 8-position.

An organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which at least one kind of compound represented by the following general formula is contained in any layer of the at least one organic layer, is an organic electroluminescent element, in which the generation of dark spots during driving is inhibited: ##STR00001##

An organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which at least one kind of compound represented by the following general formula is contained in any layer of the at least one organic layer, is an organic electroluminescent element, in which the generation of dark spots during driving is inhibited: ##STR00001##

A redox flow battery includes a cathode, an anode, a charge-carrying electrolyte, and an (a) oxidized and a (b) reduced form of an active material. The active material has the following formula: (D)-(L)-(A)-[(L)-(A)].sub.V-D.sub.Z(F1) or (D)-(L)-(A)-(L-D).sub.X (F2). In these formulae, each D is covalently bonded to an L, each L is covalently bonded to an A, x is a number from 0 to 5, v is a number from 0 to 5 and z is 0 or 1. D is an electron donor compound, L is a linker, and A is an electron acceptor compound. Each of D, L, and A has a particular structure.

This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections. ##STR00001##